EMA launches #HealthNotHype campaign on safe GLP-1 medicine use with content creators
EMA, 2025: The European Medicines Agency has launched its first social media campaign involving content creators, aiming to raise awareness about the safe and responsible use of GLP-1 receptor agonists through the #HealthNotHype initiative.
Campaign launch and scope
The campaign focuses on medicines that were initially developed to treat type-2 diabetes. EMA said that some GLP-1 receptor agonists are now also indicated for weight management in people living with obesity and weight-related health conditions. The agency noted that these medicines are effective for patients, particularly against a backdrop of rising obesity and diabetes rates worldwide.